Lipids-Pharma前接收者

可吸入、受控释放的ciproxacin内含纳米晶体

汤姆 — 卫星2021年6月26日12:30:19+00

Novel inhalable and controlled release powder formulations of ciprofloxacin nanocrystals inside liposomes (CNL) were recently developed.在这次研究中,CNL粉末存储稳定性由lyo保护者组成(即sucrose or lactose), lipids, ciprofloxacin (CIP), and magnesium stearate or isoleucine was investigated.喷雾干燥生成这些粉末,收集在<15%相对湿度>干箱中,然后存储室温度4或20RH。

Lipsomal完整性、CIP封装效率(EE)、in vitro 释放药效(IVR)、浮质性能和固态性能6个月以上都经过检验。scrose CNL粉状显示一贯亲脂完整性、气溶胶性能和受控释放CIP半年存储量4%RH同期将火药储存20%RH后,EP和气溶胶性能显著下降(p-values < 0.05),CIPIVR类比非晶状CIP液化分布法(f2 > 50)Lactose CNL在过去6个月保持高气溶胶性能,而不管存储量RH.s/p>

此外,IVR从 lactose CNL对CIP的解析显示少受控释放并与其六个月后初始值大相径庭(f2 < 50),而不管存储RHsscience/abs/pii/S037851732106141目标='blank' rel='noopener'可吸入、受控释放化学配方稳定化coproxacin内含纳米液态,《国际药理学杂志》,卷605,2021https://doi.org/10.1016/j.ijpharm.2021.120809.

Der Beitrag Storage stability of inhalable, controlled-release powder formulations of ciprofloxacin nanocrystal-containing liposomes erschien zuerst auf Pharma Excipients.

deximathone-loaddNano结构Lipid载体处理干眼病

汤姆 — Frii,2021年6月25日7:0001+00

srcs/www.pharmaexsubjects.com/wp-content/uploads/2021/06/Deximated-Nasted-Listed-Carriers-f-Treatment-Dry-Eye-served.jpg类sAll treated corneas used 50 µL of either a 0.1% (w/v) coumarin-6 solution or the same volume of an NLC solution loaded with 0.1% (w/v) coumarin-6." loading="lazy" srcset="//www.novoestroim.com/wp-content/uploads/2021/06/Dexamethasone-Loaded-Nanostructured-Lipid-Carriers-for-the-Treatment-of-Dry-Eye-Disease-scaled.jpg 2560w, //www.novoestroim.com/wp-content/uploads/2021/06/Dexamethasone-Loaded-Nanostructured-Lipid-Carriers-for-the-Treatment-of-Dry-Eye-Disease-300x234.jpg 300w, //www.novoestroim.com/wp-content/uploads/2021/06/Dexamethasone-Loaded-Nanostructured-Lipid-Carriers-for-the-Treatment-of-Dry-Eye-Disease-1024x800.jpg 1024w, //www.novoestroim.com/wp-content/uploads/2021/06/Dexamethasone-Loaded-Nanostructured-Lipid-Carriers-for-the-Treatment-of-Dry-Eye-Disease-150x117.jpg 150w, //www.novoestroim.com/wp-content/uploads/2021/06/Dexamethasone-Loaded-Nanostructured-Lipid-Carriers-for-the-Treatment-of-Dry-Eye-Disease-768x600.jpg 768w, //www.novoestroim.com/wp-content/uploads/2021/06/Dexamethasone-Loaded-Nanostructured-Lipid-Carriers-for-the-Treatment-of-Dry-Eye-Disease-1536x1200.jpg 1536w, //www.novoestroim.com/wp-content/uploads/2021/06/Dexamethasone-Loaded-Nanostructured-Lipid-Carriers-for-the-Treatment-of-Dry-Eye-Disease-2048x1599.jpg 2048w, //www.novoestroim.com/wp-content/uploads/2021/06/Dexamethasone-Loaded-Nanostructured-Lipid-Carriers-for-the-Treatment-of-Dry-Eye-Disease-600x469.jpg 600w" sizes="(max-width: 2560px) 100vw, 2560px" />

Dry eye disease (DED) or keratoconjunctivitis sicca is a chronic multifactorial disorder of the ocular surface caused by tear film dysfunction.症状包括干燥性、刺激性、不适和视觉干扰,标准处理包括润滑油和局部类固醇使用二次炎症在开发传播这一虚弱条件中起着突出作用。

解决此点,我们已经调查创新药物提供系统实验规模开发使用 dexethasone/emoji/13.0.172/2122.png' altss/www.pharmaexccidents.com/product/labrafac-lipoptile-wl-1349/最大高度:1em;"/ > 亲脂载量/a快速筛选实验室规模预编程后,所选配方以实验规模编译,粒度为19.51+++0.5Nm,封装效率99.6+++0.5%,PDI0.08和4°C扩展稳定性6个月观察发现,这种潜在的眼科配方具有高可耐性并内化能力,在ex vivoporcine角膜研究中展示相似行为,建议奥氏表面适当分布。

p>serve,ELISA用于研究实验级配方对各种炎症生物标志的影响最成功的解甲松装入NLC显示单方三叉松TNF-A生产5倍下降,MMP-9和IL-6相仿结果易编译性、可扩缩性、性能和生物标志分析显示,NLC配方可成为DED专题处理的可行选项。

ahref='https//www.pharmaexbiders.com/wp-content/uploadss/2021/06/Dexicathone-Loaded-Nanostrationd-Lipid-Carriers-s-the-Treatment-Dry-Eye-Disaces.pdf'丹达穆迪MRani S.贝海盖尔E贝哈尔G肯特D欧里利NJ欧多诺万市麦克劳林市菲茨亨里市deximetasoni-loadnationlipid载体处理干眼疾病。药理 2021 , 13 905https://doi.org/10.3390/pharmaceutics13060905

Der Beitrag Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease erschien zuerst auf Pharma Excipients.

Lipobilic盐类和基于lipid配方:加强Octreotide口服

汤姆 — 2021年6月17日09:30:06+00

Purpose

Successful oral peptide delivery faces two major hurdles: low enzymatic stability in the gastro-intestinal lumen and poor intestinal membrane permeability.脂基配方(LBF)有克服这些屏障的潜力,有效配方pti液化盐技术可增加表面亲脂性,使其更适合LBF.

>Methods ss模型治疗pide,octretoide转换为dscusLS(OCT.DoS ₂),并比较商业acte盐(OCT.OAc ₂)口服吸收研究和相关iOCT.S _{2和OCT.S _{2/subCaco-2和原位肠渗透模型显示OCT渗透性没有增加OCT.DoS ₂dds配方时显示OCT.DoS _{2 in vitro dissociation and release studies suggest that the enhanced bioavailability of OCT from SEDDS-incorporating OCT.DoS₂ is likely a result of higher partitioning into and prolonged retention within lipid colloid structures.
Conclusion
The combination of LS and LBF enhanced the in vivo oral absorption of OCT primarily via the protective effect of LBF sheltering the peptide from gastrointestinal degradation.
Read the article here
Article information: Li, P., Ford, L., Haque, S. et al. Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide. Pharm Res (2021).https://doi.org/10.1007/s11095-021-03063-3
Der Beitrag Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide erschien zuerst auf Pharma Excipients.}}}

固脂纳米粒子用于流水药

汤姆 — 元2021年6月14日12:30:27+00

Hydrophilic drugs are proficient therapeutic agents however, delivery of these drugs is a difficult task.因此,开发高效药提供系统可能需要多管齐下方法。Colloidal drug delivery systems such as emulsions, liposomes, nanoemulsions, polymeric nanoparticles, and niosomes are known to enhance drug entrapment, bioavailability, and to improve the pharmacokinetic profiles of hydrophilic drugs.

Highlights

Delivery of hydrophilic drugs using solid lipid nanoparticles (SLNs).

Enhance entrapment into SLNs by modification of traditional methods.

Enhance entrapment into SLNs by drug modification.

Improved pharmacokinetic profile of hydrophilic drugs.

However, issues such as drug leakage and burst release are frequently reported with such systems. Solid lipid nanoparticles (SLNs) were developed as an alternative to the traditional colloidal drug carriers to overcome these issues.sls作为疏水药载体已被广泛研究,但流水分子的提供仍是一个挑战。

Hence,当前审查侧重于使用 sls交付流水药时使用的不同方法网站不仅讨论传统合成方法的各种修改,还强调水益药本身的修改,帮助高效绑入SLNs药商。

帕特拉瓦固脂纳米粒子供流水药用,《控制释放杂志》,卷335,2021https://doi.org/10.1016/j.jconrel.2021.05.032.

Der Beitrag Solid lipid nanoparticles for hydrophilic drugs erschien zuerst auf Pharma Excipients.

过程和配方参数对通过双重离心制备固脂纳米粒子

汤姆 — 太阳2021年6月13日07:30:21+00

A promising strategy to formulate poorly water-soluble active pharmaceutical ingredients (APIs) is the application of these substances in solid lipid nanoparticles.药载系统常备高压同质化使用脂质熔化。

While对大规模生产非常有用,这种方法耗资颇多,不允许同时处理多样样本,例如筛选目的正因如此,引入替代制造过程双重离心法以制作固态脂纳米粒子离散成分直接加权为2mL容器室温,无需准备混合前仿真因加热离心机样本额外旋转并加研磨介质实现样本密集压强。

Dependent on the process set-up like grinding media size, filling ratio or process temperature and the composition of the lipid formulation, the achieved particles sizes were below 200 nm and had a narrow, monomodal size distribution.

Download the full article as a PDF here or read it here

Materials: The triglycerides trimyristin (Dynasan® 114, T_m = 56 °C), tripalmitin (Dynasan® 116, T_m = 66 °C) and tristearin (Dynasan® 118, T_m = 73 °C) from Hüls AG/Cremer Oleo (Witten, Germany) were kind gifts from the manufacturer.For the stabilization of the dispersions, poloxamer 188 (P188, Kolliphor® P188, BASF, Ludwigshafen, Germany!使用制造厂家的同类礼品。Sodium azide(Rose,Karlsruhe,德国)用作防腐剂使用所有配方注水.

2mLd-tist-Top-vial编译自AndreasHetichGmbH和CoKGYtrium稳定二叉珠四大使用(dsub>GM =0.1-0.2mm,0.3-0.4mm,0.5-0.7mm和0.8-1.0mm)珠子有球状形状和素密度6.05kgdsup3sup3过程和配方参数对通过双重离心制作固脂纳米粒子的影响,国际药理学杂志:X卷32021https://doi.org/10.1016/j.jpx.2021100085.

油脂微粒细粉-喷干过程开发优化

汤姆 — 弗里,2021年6月11日5:30:19+00

Objectives: Performed studies were focused on developing spray drying technique for aqueous dispersion of solid lipid microparticles (SLM) by selecting appropriate process parameters and assessing their impact on the process and properties of the obtained dry SLM powders.

Significance: Spray drying allows to obtain SLM in a dry powder form when the liquid form does not present sufficient long-term stability (e.g.span++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++输入温度和进料速率选择过程参数监测选择响应值、产量和质量属性最终产品,即粒度大小、水分含量和火药流性第一步优化流程参数用模型活性物质干解 sortives:bellosporine和spinolactone.sps类squal=u-h4u-m-topu-mgin-xsserve温度90摄氏度和摄取速率2.4ml/minstaric80°C和3ml/min进程参数优化 plabo placebo formulations proved to be equally effective when SLM with the same composition and with model active substance were subjected to drying.

Download the full article as a PDF here or read it here

Materials: Cyclosporine A (CsA) was obtained from LC Laboratories (Boston, MA, USA) and Compritol 888 ATO (glyceryl behenate) from Gattefossé (Saint-Priest, France).Spironactone(SPIR),stearicacript80polyvinylpyrrolidone (PVP) was from BASF (Ludwigshafen, Germany).使用的其他化学品都具有分析试剂等级。

form信息:Eliza Wolska,Fine微粒粉-喷干过程开发优化药送科技杂志,2021年https://doi.org/101016/jdst.2021104.

可缩放生产含AmptericinB

汤姆 — 图族2021年6月10日2.30:12+00

ispid-Nanop粒子-Contain-Amphtericin-B.gif类s含脂化合物的配方制造可能耗时难解溶性问题。

我们开发出快速可扩缩方法,使用快速混合技术生成单脂纳米粒子配方siRNA、trigecripeds和hybilic弱基药使用这种方法诱捕疏水小分子AmphericinB(AmpB),一种乙醇中不可溶解的疏水药研究中介绍的三个原型取自LNP-siRNA系统、三环纳米粒子和亲词系统低温传输电子显微镜显示所有三种LNP-AmpB配方保留父子结构特征(无AmpBLNP),粒子稳定至少1个月。

所有配方显示与AMBIOSM相似体毒性剖面关键是,配方比试管效果研究中的安比瑟提高2.5倍IC ₅₀对真菌生长抑制ahrefs.org/doi/dubs.acs.org/cs.langmuir1.0530库尔卡尼市陈山市元义市谭市Langmuir Article ASAP.DOI:10.1021/acs.langmuir.1c00530

Der Beitrag Scalable Production of Lipid Nanoparticles Containing Amphotericin B erschien zuerst auf Pharma Excipients.

纳米结构化脂载体增强tretinoin安全剖面:体外健康人类志愿者研究

汤姆 — Tue20218Jun14:50:44+00

Aim: To enhance the tretinoin (TRE) safety profile through the encapsulation in nanostructured lipid carriers (NLC).

Materials & methods: NLC-TRE was developed using a 2³ experimental factorial design, characterized (HPLC, dynamic light scattering, differential scanning calorimetry, x-ray diffraction analysis, transmission electron microscopy, cryo-transmission electron microscopy) and evaluated by in vitro studies and in healthy volunteers.

Results: The NLC-TRE presented spherical structures, average particle size of 130 nm, zeta potential of 24 mV and encapsulation efficiency of 98%.NLC-TRE保护TRE避免氧化(p <0.0001)并推广上下文定位(p <0.0001)与营销产品相比,两者均0.05%TREThe in vitro assay on reconstructed human epidermis and the measurement of transepidermal water loss in healthy volunteers demonstrated an enhanced safety profile in comparison to the marketed product (p < 0.0002).

Conclusion: The NLC-TRE enhances the epidermal targeting and safety profile of TRE, representing a potential safer alternative for the topical treatment of skin disorders using TRE.

Read the article here

Article information: Flávia A Lima, Raquel VR Vilela, Rodrigo L Oréfice, Izabela R Silva, Eduardo CO Reis, Larissa AC Carvalho, Silvya S Maria-Engler, Lucas AM Ferreira, and Gisele AC Goulart.span类sspan/span/span/span类smessions/spans/span

流益绑定器对基脂持续释放矩阵稳定性的影响

Philippe语言 — mon,07Jun202109:30:04+00

Dose dumping is the major drawback of sustained release (SR) matrices.当前研究旨在开发稳定的基于脂质的Quitiapinefumate矩阵使用Geleol ^TMsup>TM/supEF/grefs/开发配方使用双螺旋熔粒法和直接压缩技术。

脂集中度10-20%产生16-24h. 表格HPCEF绑定符跟踪零序释放动能.

固态定性微粒微量分扫描显示脂质晶体性质傅里叶变换红外光谱显示配方成分之间没有交互作用TSMG和DC压缩矩阵持续释放超过1624h加速存储6个月后,TSMG矩阵保留持续释放特征而不倾入酒精量,而DC矩阵则导致倾出量推算矩阵完整性损失和脂分分离由此得出的结论是,软化绑定器统一分布成熔化脂载体导致TSMG稳定矩阵ahrfs/www.sciousbent.com/science/abs/bi/S0921883121002648目标sRepka/p>Der Beltrag < arel=nept'href=s/www.pharmers-stiapine-furate/

ketorac加注微模法开发使用D最优实验法

Markuskobel — Sun,06Jun202102:30:14+00

Aim of the present study was to evaluate the potential of microemulsions for the transdermal delivery of ketorolac tromethamine.伪代相图3D最优混合设计用于开发期望属性微模17试运行使用三种变量执行,石油百分数、水和表面活性与共冲比优化比,而所调查的响应为百分数传输和Globule尺寸微浮系统由eclyptus油类组成,Metes Salicylate,

See the article here

Tripti Shukla, Sharad Prakash Pandey, Piyuh Khare, Neeraj Upmanyu,
Development of ketorolac tromethamine loaded microemulsion for topical delivery using D-optimal experimental approach: Characterization and evaluation of analgesic and anti-inflammatory efficacy,
Journal of Drug Delivery Science and Technology, 2021, 102632,
https://doi.org/10.1016/j.jddst.2021.102632.

Der Beitrag Development of ketorolac tromethamine loaded microemulsion for topical delivery using D-optimal experimental approach: Characterization and evaluation of analgesic and anti-inflammatory efficacy erschien zuerst auf Pharma Excipients.

脂纳米粒子大小对mRNA疫苗免疫性的影响

汤姆 — 2021年6月5日07:30:21+00

Lipid nanoparticles (LNP) are effective delivery vehicles for messenger RNA (mRNA) and have shown promise for vaccine applications.但没有发布详细描述LNP生物物理特性如何影响疫苗性能的报告。

在我们手中,对MRNALNP疫苗回溯分析Vivo研究显示LNP粒子大小和小鼠免疫性之间的关系使用各种成份LNP深入调查,我们设计了一系列研究系统改变LNP粒子大小而不改变脂质组成并评价LNP生物特性和免疫性。

小直径LNPHassett、Jaclyn Higgins、Angela Woods、Becalievy、Yan Xia、ChiaewenJoyce Xiao、Edward Acosta、Örn Almarsson、MelissaJ摩尔Luis布里托油脂纳米粒子大小对mRNA疫苗免疫性的影响,Journal受控释放,卷335,2021https://doi.org/10.1016/j.jconrel.2021.05.021.

Ingredients and Excipients in the COVID-19 Vaccines

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

Der Beitrag Impact of lipid nanoparticle size on mRNA vaccine immunogenicity erschien zuerst auf Pharma Excipients.

聚合和lipid纳米粒子:小儿科应用是什么

Philippe语言 — 2021年6月3日2.30:31+00

This review aims to provide the state of the art on polymeric and lipid nanoparticles, used or suggested to approach pediatric diseases' problems and needs, and to inspire new researches in this field.数种药目前无法配方供小儿科病人使用美国儿科配方计划建议应用新技术小儿药配方,例如纳米技术文献分析显示聚合物和脂质纳米粒子已被广泛研究治疗儿科疾病,并已在临床实践中使用核聚物纳米粒子和脂质尽管如此,这些研究几乎完全侧重于儿科癌症处理纳米医学可解决儿科疾病和医学的许多需求,但无法获取药代物学数据、药物安全性和有效性和儿科病人纳米粒子安全性限制开发以纳米粒子为基础的儿科新药单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片/单片s/www.mdpi.com/1999-4923/13/5/670/htm2021年5月13(5)PMCID: PMC8148525.

Natural and synthetic polymer used to make pediatric nanoparticles (created with Biorender)

Natural Polymers: Albumin, Zein, Whey, Apotransferrin, Lactoferrin, Chitosan

Synthetic Polymers: Polyethylene Glycol, Poly(alkyl cyanoceyate), Poly(lactic-co-glycolic acid), Poloxamer 188, Hypromellose acetate succinate, Polyvinlypryrrodidone K30, Poly(e-caprolactone), Poly(lactic acid) Eudragit RS PO/RL PO, Poly(methyl mathacrylate), Poly(beta-amino ester)

Conclusions
Polymeric and lipid NPs have been widely studied to treat pediatric diseases, but only a few are used in therapy and only to treat pediatric cancers.高度关注使用前接收者安全易升级编程方法,当然还关注大小以获取安全载体。

因此,NP开发新儿科药时可能比较有利,不仅治疗癌症,而且还治疗慢性病,避免标签外使用和即时配方NP可按EMA和FD的要求,作为平台开发适合每个小类的适龄配方。

/derBetrag href=s/www.pharmaexsubjects.com/paedatric/congic-lipid-nanoparts/

TPGS和chondroitinulfate双变脂-Actmin纳米系统

汤姆 — Thu,2021年5月20日

Multidrug resistance (MDR) remains the primary issue leading to the failure of chemotherapy.In this study, a d-α-tocopherol polyethylene 1000 glycol succinate (TPGS) and chondroitin sulfate (CS) dual-modified lipid-albumin nanosystem was constructed for targeted delivery of paclitaxel (PTX) in treating MDR cancer.

Highlights

A lipid-albumin nanosystem was developed to treat multidrug resistance cancer.

Introduction of chondroitin sulfate promoted CD44-mediated endocytosis.

TAL/PTX@CS showed notable antitumor efficacy and good biosafety.

The obtained nanosystem (TLA/PTX@CS) had an average size of around 176 nm and a negative zeta potential of around −18 mV.TPGS确认改善PTX细胞内积聚并便利脂性单片反射纳米系统外CS外壳功能化TLA/PTX@CS通过CD44受体中位内分解输入MDR乳腺癌CS shell was degraded by concentrated hyaluronidase in the lysosomes, thereby releasing PTX into cytoplasm and inhibiting cell proliferation. In vivo studies revealed that TLA/PTX@CS possessed prolonged blood circulation, resulting in elevated tumor accumulation, excellent antitumor efficacy with a tumor inhibition ratio of 75.3%, and significant survival benefit in MCF-7/MDR tumor-bearing mice.

Hence, this TPGS and CS dual-modified lipid-albumin nanosystem provides a promising strategy for targeted delivery of chemotherapeutic drug and reversal of MDR in cancer treatment.

Read the article here

Article information: Kaipei Luo, Feng Xu, Tianyi Yao, Jianping Zhu, Hua Yu, Guangji Wang, Juan Li.TPGS和chondroitinulfate双变脂单纳米系统定向交付抗多药抗癌药剂,国际生物宏素杂志,第183卷,2021年https://doi.org/10.1016/j.ijbiomac.2021.05.070.

Der Beitrag TPGS and chondroitin sulfate dual-modified lipid-albumin nanosystem for targeted delivery of chemotherapeutic agent against multidrug-resistant cancer erschien zuerst auf Pharma Excipients.

默克-MilliporeSigma应用

汤姆 — 2021年5月12日Wed12:30:21+00

Lipids are the most widely used delivery system for mRNA therapeutics.lipid纳米粒子提供安全有效药送系统以COVID-19和其他疾病为对象Watch Merck's animated video about lipid nanoparticles and lipids here:

//www.novoestroim.com/wp-content/uploads/2021/05/Merck-lipids-video.mp4

Your global partner for the manufacturing of synthetic lipids

A GMP-scalable process which yields a high-quality lipid is essential to lipidic drug product development and manufacturing.s/www.pharmaex新手.com/merck-a-leader- in-science/并提供脱机目录优化稳定性、溶解性及处理特征需要脂质混合时,可提供液化喷干。

our网站遍及全世界,包括西欧,使用ICHQ7达标质量系统满足高调生产合成脂质需求Committed to consistently high product quality, reliability of supply, and short delivery timelines, we assist you through all phases of clinical development and commercialization and help you meet your development milestones.

We manufacture portfolio lipids, PEGylated lipids, cationic/ ionizable lipids, and targeted lipids.

Merck's Offerings:

Support in every phase of development and marketing
cGMPs and site standards that follow the concepts of ICH Q7
Consistently high product quality from grams to tons

Stability studies and analytical method development and validation
Regulatory expertise and counsel from a dedicated team
An excellent track record of customer and FDA audits

Merck‘s portfolio of GMP lipids includes:

Neutral lipids	Cationic lipids	PEG lipids	Phospholipids	Others
Synthetic cholesterol** Isomeric mixture 1,3 and 1,2-GDO Tripalmitin	(R,S)-DOTAP Cl or (R)/(S) (R)- DODMA (R)- DOTMA** MoChol*	DSG PEG 2000 DMG PEG 2000	DOPC DPPC DOPE DSPC**	Squalene** Fatty acid: Palmitic acid CHEMS

*Some applications of these lipids may require a license from Merck's partners.
**These products are typically applied in COVID-19 vaccine formulations

Keep on reading here

For more information, contact us:

Name *

First

Last

Email *

Company *

Address

Address Line 1

Address Line 2

City

State / Province / Region

Postal Code

Country

Comment or Message *

Name

See another interesting article on successful drug development with synthetic lipids

Successful drug development with synthetic lipids:
critical aspects and strategies

Der Beitrag Lipids for pharmaceutical applications from Merck – Millipore Sigma erschien zuerst auf Pharma Excipients.

提高S-Adenosyl-L-Methionine口服生物可用性研究:SLN和SLNN纳米复合粒子

汤姆 — Thu,065202109:3014+00

The endogenous molecule, S-adenosyl-L-methionine (SAMe) is a key factor due to its role in the methylation cycle and modulation of monoaminergic neurotransmission.多位精神失常与单亚胺基系统相关联,因此SAMe血液和脑膜流体水平对大萧条治疗很重要在这次研究中,为增加SAMe有限口服生物可用性准备了固态脂质粒子,SLN基纳米复合粒子(SAME-SLN-NC)利用进化聚合物对肠膜系统作被动选择得到进一步发展In this manner, it was also aimed to protect SAMe loaded SLN from harsh gastric environment as well as hepatic first-pass metabolism.

Highlights

To increase the oral bioavailability of SAMe, a naturally occurring molecule which has crucial role in many biochemical pathways, for depression treatment.

To obtain SLN nanocomposite particles using enteric polymers to protect SAMe loaded SLN from the gastric environment.

To improve intestinal SAMe permeability via passively targeted lipid-based drug carrier systems.

Dynamic light scattering (DLS) analysis of SLN was performed, drug content was measured, SAMe release patterns were examined and the permeation ability of SAMe was investigated by the Parallel Artificial Membrane Permeability Assay (PAMPA) to characterize SAMe loaded SLN formulation.PAMPA结果显示SAME-SLN平均粒度242纳米显示SAME渗透性比纯药强SLN纳米复合粒子获取延迟释放毒品表示保护酸气介质中装药SLNSAME溶液或粒子悬浮用0.45(w/v)hyprosyme药代参数显示,口服SLN配方后SAMe相对生物可用性提高归结于通过淋巴路径完全吸收脂质矩阵sup>d/sup>和2sup>d/sup>和4sup>s/sup提高S-Adenosyl-L-Methionine口服生物可用性研究:SLN和SLNNNhttps://doi.org/10.1016/j.chemphyslip.20211086.

Der Beitrag